LaFleur & Godfrey LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 0.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 97,322 shares of the medical technology company’s stock after acquiring an additional 559 shares during the quarter. Stryker Corporation accounts for approximately 3.6% of LaFleur & Godfrey LLC’s holdings, making the stock its 7th biggest holding. LaFleur & Godfrey LLC’s holdings in Stryker Corporation were worth $13,506,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Lockheed Martin Investment Management Co. purchased a new position in shares of Stryker Corporation during the second quarter worth approximately $1,249,000. JPMorgan Chase & Co. raised its stake in shares of Stryker Corporation by 276.9% during the first quarter. JPMorgan Chase & Co. now owns 269,555 shares of the medical technology company’s stock worth $35,487,000 after acquiring an additional 198,035 shares in the last quarter. BB&T Corp raised its stake in shares of Stryker Corporation by 5.7% during the second quarter. BB&T Corp now owns 56,546 shares of the medical technology company’s stock worth $7,847,000 after acquiring an additional 3,060 shares in the last quarter. British Columbia Investment Management Corp raised its stake in shares of Stryker Corporation by 10.7% during the first quarter. British Columbia Investment Management Corp now owns 133,596 shares of the medical technology company’s stock worth $17,588,000 after acquiring an additional 12,871 shares in the last quarter. Finally, Hartland & Co. LLC raised its stake in shares of Stryker Corporation by 1.4% during the first quarter. Hartland & Co. LLC now owns 1,860 shares of the medical technology company’s stock worth $245,000 after acquiring an additional 25 shares in the last quarter. 74.18% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Stryker Corporation (SYK) opened at 142.50 on Monday. The company has a market cap of $53.30 billion, a PE ratio of 31.81 and a beta of 0.81. The stock’s 50 day moving average is $144.06 and its 200-day moving average is $138.10. Stryker Corporation has a one year low of $106.48 and a one year high of $148.84.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the consensus estimate of $1.51 by $0.02. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.39 earnings per share. Equities research analysts expect that Stryker Corporation will post $6.46 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be paid a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.19%. Stryker Corporation’s dividend payout ratio is currently 37.95%.
Several brokerages recently commented on SYK. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $148.00 target price on shares of Stryker Corporation in a research note on Thursday, August 24th. Needham & Company LLC raised shares of Stryker Corporation from an “underperform” rating to a “hold” rating in a research note on Friday, August 25th. Cantor Fitzgerald began coverage on shares of Stryker Corporation in a research note on Thursday, June 29th. They issued a “neutral” rating and a $153.00 target price on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $160.00 target price (up from $155.00) on shares of Stryker Corporation in a research note on Monday, July 10th. Finally, Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. Stryker Corporation presently has a consensus rating of “Hold” and a consensus target price of $145.73.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $146.36, for a total transaction of $731,800.00. Following the transaction, the insider now owns 88,207 shares in the company, valued at $12,909,976.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Floyd sold 19,305 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,429 shares of company stock worth $3,686,927. Insiders own 7.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/09/11/stryker-corporation-syk-holdings-lifted-by-lafleur-godfrey-llc.html.
Stryker Corporation Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.